EcoDrugPlus

5'-Nucleotidase Ecto

Ensembl ID : ENSSAUG00010007022
Gene Symbol: NT5E
1 Cross references
215 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSSAUG00010026291
Gene Symbol: LOC115566087
3 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSSAUG00010027603
Gene Symbol: HTR2B
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSAUG00010026290
Gene Symbol: HTR1B
3 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSAUG00010007652
Gene Symbol: HTR1B
1 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSAUG00010020477
Gene Symbol: HTR1F
1 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSAUG00010017725
Gene Symbol: HTR2A
3 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSAUG00010009045
Gene Symbol: LOC115590333
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSAUG00010013486
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSAUG00010013576
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSAUG00010002579
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSAUG00010013444
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).